Focused On-demand Library for Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:

Cap methyltransferase 2; Cap2 2'O-ribose methyltransferase 2; FtsJ methyltransferase domain-containing protein 1; Protein adrift homolog

Alternative UPACC:

Q8IYT2; B2RCD5; D3DWS1; Q8NE77; Q8NFR5; Q9H8Z4; Q9NUS3; Q9NXF5


Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 2, also known as Cap methyltransferase 2, plays a crucial role in mRNA processing. It is responsible for the S-adenosyl-L-methionine-dependent methylation of mRNA cap2 2'-O-ribose, enhancing the stability and efficiency of mRNA translation. This protein's ability to recognize and methylate the ribose of the second nucleotide of a capped mRNA, regardless of the N(7) methylation status of the guanosine cap, underscores its specificity and importance in RNA metabolism.

Therapeutic significance:

Understanding the role of Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 2 could open doors to potential therapeutic strategies. Its pivotal function in mRNA processing and translation regulation suggests that modulating its activity could influence gene expression patterns, offering new avenues for treating diseases with underlying genetic and mRNA processing anomalies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.